Form 4: Haemonetics CFO James D'Arecca Reports Vesting of Performance Share Units and Tax-Related Share Disposition

Haemonetics Corporation's EVP and Chief Financial Officer, James D'Arecca, reported the acquisition of 12,221 common shares from vested performance share units and the disposition of 5,864 shares for tax obligations on May 30, 2025.

Summary

• James D'Arecca, EVP and Chief Financial Officer of Haemonetics Corp (HAE), acquired 12,221 shares of common stock on May 30, 2025.
• These shares were earned from a performance share unit (PSU) award granted on May 16, 2022, based on the company's total shareholder return relative to the S&P MidCap 400 Index for the performance period from May 16, 2022, to May 15, 2025.
• The Compensation Committee of the Board of Directors certified the performance on May 30, 2025.
• Following this acquisition, Mr. D'Arecca beneficially owned 34,156 shares, which includes previously reported unvested restricted stock units (RSUs).
• Concurrently, Mr. D'Arecca disposed of 5,864 shares of common stock on May 30, 2025, at a price of $69.38 per share.
• This disposition was for shares withheld to cover tax obligations related to the vesting of the PSUs.
• After the tax-related disposition, Mr. D'Arecca's beneficial ownership stands at 28,292 shares, also including previously reported unvested RSUs.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The vesting of performance share units indicates that the company met its performance targets, which is a positive sign for shareholders. The subsequent share disposition for tax purposes is a routine and expected event, not indicative of negative sentiment or a lack of confidence.

Positives

• The vesting of 12,221 performance share units indicates that Haemonetics Corp met or exceeded the performance targets set for the May 16, 2022, to May 15, 2025, period, specifically regarding its total shareholder return relative to the S&P MidCap 400 Index.
• This successful vesting aligns management's incentives with shareholder value creation.

Negatives

• The disposition of 5,864 shares at $69.38 per share for tax obligations reduces the direct shareholding of the EVP and CFO, though this is a standard practice for equity compensation.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation for a senior executive at Haemonetics Corp, a company operating in the medical technology and healthcare industry. Such filings are common across all industries as part of executive compensation plans and do not inherently reflect broader industry trends, but rather the specific performance and compensation structure of the individual company.

Stakeholder Impact

• Shareholders: The vesting of performance-based equity awards for a key executive aligns management incentives with shareholder returns, potentially signaling confidence in the company's performance. The tax-related sale is a minor, routine event.

Key Dates

Keywords

Haemonetics Corp, HAE, Form 4, Insider Transaction, James D'Arecca, EVP Chief Financial Officer, Performance Share Units, PSU, Restricted Stock Units, RSU, Equity Compensation, Share Vesting, Tax Withholding, Beneficial Ownership